While most of these drugs are actually GLP-1 agonists, they all work by modifying GLP-1 activity, but with key differences in their intended use, dosage, and effectiveness
At its core is Tirzepatide, a next-generation dual agonist that targets both GLP-1 and GIP receptors to help regulate appetite, support metabolic balance, and drive meaningful weight loss
These patches can adjust drug release based on the patients current health status, enabling personalized therapy
Reviews focusing on semaglutide specifically [65] and broader examinations of GLP-1 RA mechanisms and clinical data have consistently concluded that these agents represent important therapeutic advances
Both medications are administered through subcutaneous injections
For someone on a GLP-1 medication where transit time is already extended, this can make the difference between a comfortable daily bowel movement and going 3-4 days without one